Payment overview · 2025
General Payments
$2,050.75
71 reported records · 23 companies
Healthcare provider profile · identity verified
Alejandro Cabigting Dizon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, FL · NPI 1225057193
Verified facts
What the public records show
CMS Open Payments records show Alejandro Cabigting Dizon, MD received $2,050.75 in general payments during 2025 across 71 reported records.
ABBVIE INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $312.61 | 15.2% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $255.58 | 12.5% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $242.16 | 11.8% | 7 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $132.55 | 6.5% | 1 | 2025 |
| Verrica Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.00 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.68 | 6.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.97 | 5.7% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $105.61 | 5.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.58 | 4.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $87.04 | 4.2% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $79.91 | 3.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.30 | 3.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.79 | 2.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.75 | 2.5% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $30.54 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.88 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.19 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.17 | 1.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $21.65 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.98 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.59 | 0.8% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $15.57 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,050.75 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $287.44 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $255.58 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $191.88 | 4 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $132.55 | 1 | 2025 |
Source payment records
|
|||||
| YCANTH Normalized: ycanth |
Drug | Verrica Pharmaceuticals Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $123.68 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $105.61 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $94.58 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $87.04 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.07 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $79.91 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.75 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.29 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.57 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $30.54 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $30.54 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $30.15 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 168 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
159 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 843 | 266 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 194 |
| Losartan Potassium | Losartan Potassium | 559 | 163 |
| Metformin Hcl | Metformin Hcl | 458 | 127 |
| Lisinopril | Lisinopril | 369 | 109 |
| Omeprazole | Omeprazole | 328 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 70 |
| Gabapentin | Gabapentin | 259 | 107 |
| Carvedilol | Carvedilol | 254 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 70 |
| Montelukast Sodium | Montelukast Sodium | 178 | 67 |
| Alendronate Sodium | Alendronate Sodium | 172 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 170 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 79 |
| Eliquis | Apixaban | 168 | 61 |
| Simvastatin | Simvastatin | 168 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 45 |
| Farxiga | Dapagliflozin Propanediol | 159 | 47 |
| Jardiance | Empagliflozin | 159 | 45 |
| Alprazolam | Alprazolam | 158 | 36 |
| Furosemide | Furosemide | 158 | 67 |
| Trazodone Hcl | Trazodone Hcl | 153 | 53 |
| Potassium Chloride | Potassium Chloride | 145 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 54 |
| Ozempic | Semaglutide | 140 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 134 | 40 |
| Sertraline Hcl | Sertraline Hcl | 124 | 46 |
| Clonidine Hcl | Clonidine Hcl | 122 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 48 |
| Meloxicam | Meloxicam | 107 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 47 |
| Ezetimibe | Ezetimibe | 99 | 35 |
| Ibuprofen | Ibuprofen | 96 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 30 |
| Tradjenta | Linagliptin | 85 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 28 |
| Famotidine | Famotidine | 81 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 23 |
| Allopurinol | Allopurinol | 74 | 29 |
| Spironolactone | Spironolactone | 73 | 35 |
| Valsartan | Valsartan | 71 | 22 |
| Methocarbamol | Methocarbamol | 70 | 36 |
| Januvia | Sitagliptin Phosphate | 69 | 21 |
| Tramadol Hcl | Tramadol Hcl | 69 | 54 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 20 |
| Mounjaro | Tirzepatide | 66 | 14 |
| Donepezil Hcl | Donepezil Hcl | 65 | 13 |
| Azithromycin | Azithromycin | 64 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 16 |
| Mirtazapine | Mirtazapine | 64 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 27 |
| Fenofibrate | Fenofibrate | 60 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 15 |
| Lactulose | Lactulose | 58 | 34 |
| Prednisone | Prednisone | 55 | 45 |
| Azelastine Hcl | Azelastine Hcl | 54 | 28 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 14 |
| Buspirone Hcl | Buspirone Hcl | 52 | 14 |
| Clonazepam | Clonazepam | 52 | 12 |
| Irbesartan | Irbesartan | 52 | 13 |
| Meclizine Hcl | Meclizine Hcl | 52 | 20 |
| Ondansetron Odt | Ondansetron | 52 | 44 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 41 |
| Cephalexin | Cephalexin | 49 | 41 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 16 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Finasteride | Finasteride | 45 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 42 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 19 |
| Celecoxib | Celecoxib | 41 | 19 |
| Nifedipine Er | Nifedipine | 41 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Atenolol | Atenolol | 38 | 13 |
| Levetiracetam | Levetiracetam | 38 | 14 |
| Mupirocin | Mupirocin | 37 | 20 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 29 |
| Metformin Hcl Er | Metformin Hcl | 36 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 19 |
| Glipizide | Glipizide | 34 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Ivermectin | Ivermectin | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Risperidone | Risperidone | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Midodrine Hcl | Midodrine Hcl | 31 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 21 |
| Hydrocortisone | Hydrocortisone | 30 | 15 |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Entresto | Sacubitril/Valsartan | 28 | 15 |
| Colchicine | Colchicine | 27 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 18 |
| Pregabalin | Pregabalin | 27 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 11 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 15 |
| Permethrin | Permethrin | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 21 |
| Trulance | Plecanatide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 19 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Nystatin | Nystatin | 19 | 17 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Baclofen | Baclofen | 14 | 11 |
| Cefdinir | Cefdinir | 14 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,050.75 · 71 records | ABBVIE INC. | AREXVY, ARISTADA, Arikayce, BREZTRI, Brinsupri, CAPLYTA, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, JASCAYD, Kerendia, LINZESS, LYBALVI, MOUNJARO, NEUROSTAR TMS THERAPY SYSTEM, NURTEC ODT, Natroba, OFEV, Omnipod, Ozempic, REXULTI, Rybelsus, Spinosad, VRAYLAR, WATCHMAN FLX, Wegovy, YCANTH, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error